-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Primary mediastinal large B-cell lymphoma (PMLBL) is a unique pathological solid disease characterized by an anterior mediastinal mass, which is thought to originate from thymic medullary B cells and accounts for approximately 2% of pediatric mature B-cell lymphomas
.
Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone + rituximab (DA-EPOCH-R) regimens have been proven to be effective without radiotherapy.
Adult patients with primary mediastinal large B-cell lymphoma provide superior survival rates
.
However, no relevant prospective studies have been evaluated in children and adolescents with PMLBL
child
Researchers such as Burke GA Amos conducted an international, single-arm phase II trial, recruiting PMLBL patients under 18 years of age to receive 6 courses of DA-EPOCH-R treatment
.
The primary endpoint is event-free survival (EFS)
EFS and OS of test children
EFS and OS of test childrenA total of 46 patients were included
.
The median age is 15.
The 4-year EFS was 69.
Heart blood vessels
In summary, the results of the study showed that the DA-EPOCH-R regimen failed to improve the event-free survival rate of children with primary mediastinal large B-cell lymphoma
.
Further research is needed to determine the best treatment for children and adolescents with this lymphoma
The DA-EPOCH-R regimen did not improve the event - free survival rate of children with primary mediastinal large B-cell lymphoma Survival rate
Original source:
Original source:Burke GA Amos, Minard-Colin Veronique, Aupérin Anne et al.
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial In this message
